|Dr. Yuval Cohen||CEO & Director||810.55k||N/A||1975|
|Mr. Sean F. Moran CPA, M.B.A., CPA, MBA||Chief Financial Officer||520k||N/A||1958|
|Dr. Barbara White||Head of Research & Chief Medical Officer||570.7k||N/A||1950|
|Ted Jenkins||Sr. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Dr. Mark A. Tepper||Co-Founder & Consultant||N/A||N/A||1957|
|Scott Constantine||Sr. Director & Head of Clinical Operations||N/A||N/A||N/A|
|Mr. Craig Stuart Millian M.B.A.||Chief Commercial Officer||N/A||N/A||1968|
|Sergei Atamas||Exec. Director of Research||N/A||N/A||N/A|
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.
Corbus Pharmaceuticals Holdings, Inc.’s ISS Governance QualityScore as of November 1, 2019 is 7. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 4; Compensation: 9.